Rectal Cancer Deaths Rising Rapidly Among Older Millennials, New Data Shows

Rectal cancer mortality among Americans in their 30s and 40s is climbing two to three times faster than colon cancer deaths in the same age group, according to new research presented at Digestive Disease Week 2026 [1]. The trend — confirmed across 24 years of CDC death records — has prompted oncologists to call the situation "a medical crisis" [1], even as some epidemiologists urge caution about how the numbers are framed.

The findings land at a moment when colorectal cancer has already become the leading cancer killer of Americans under 50 [2]. An estimated 158,850 new colorectal cancer cases and 55,230 deaths are projected in the United States for 2026, with roughly one-third of those deaths occurring in people under 65 [1][3].

The Numbers: How Fast Is Rectal Cancer Mortality Rising?

Researchers at SUNY Upstate Medical University, led by gastroenterology fellow Mythili Menon Pathiyil, analyzed U.S. death records from 1999 to 2023 in the CDC WONDER database for adults aged 20 to 44 [1][4]. They found that rectal cancer death rates are accelerating two to three times faster than colon cancer rates across every demographic subgroup studied [1].

Colorectal cancer incidence among adults under 50 has been increasing at roughly 3% per year since the late 1990s [3]. Mortality rates in this age group have risen at approximately 1% annually since 2004 [3]. Among adults aged 50 to 64, mortality has also begun climbing — at about 1% per year since 2019 — while death rates in adults 65 and older continue to fall by more than 2% annually [3].

The birth-cohort effect — the observation that each successive generation faces higher risk at the same age — is central to the data. Incidence rates for 40-year-olds born in 1970 reached 24.4 per 100,000, compared to 18.3 per 100,000 for those born in 1950 [5]. Generation X and millennials show the steepest generational escalation. A Lancet Oncology analysis of population-based registry data across multiple countries found that individuals born in the 1990s face at least four-fold higher early-onset colorectal cancer risk than those born in the 1960s [6].

Source: DDW 2026 / SUNY Upstate Medical University

Data as of Apr 23, 2026CSV

Incidence, Late Diagnosis, or Both?

The rise in deaths appears to be driven by both increasing incidence and persistently late-stage diagnoses. Rectal cancer now accounts for 32% of all colorectal cancer diagnoses, up from 27% in the mid-2000s [3]. Nearly half — 45% — of all new colorectal cancer cases now occur in adults under 65, compared to 27% in 1995 [3].

Stage at diagnosis is a critical factor. Three in four colorectal cancers in adults younger than 50 are regional or distant stage at the time of diagnosis, and roughly 27% are distant-stage [2][3]. The five-year survival rate for localized disease is 95%, but drops sharply for later-stage diagnoses [3][7]. This means the late-detection pattern among younger patients is directly translating into higher mortality.

A major contributor to late detection is diagnostic delay. Young adults experience an average seven-month gap between symptom onset and diagnosis, compared to approximately one month for older patients [1][4]. When a younger patient presents with rectal bleeding, physicians frequently attribute it to hemorrhoids rather than ordering a colonoscopy [2].

"Colorectal cancer is no longer considered predominantly a disease of older adults," Pathiyil said. "Rectal cancer, especially, is becoming a growing problem in younger individuals" [4].

Who Is Hit Hardest?

The burden falls unevenly. Hispanic adults experienced the fastest-growing rectal cancer mortality rates of any demographic group in the study, and those living in western U.S. states saw the steepest geographic rise [1][4].

Racial disparities in colorectal cancer are long-documented. Among Black Americans under 50, 11% are diagnosed with colorectal cancer, more than double the overall population rate [8]. Black patients are less likely to receive guideline-concordant care — including surgery, radiation, and chemotherapy — even after controlling for age, insurance status, and income, resulting in shorter survival [8][9]. Health insurance explains roughly 28% of the treatment disparity for colon cancer and 22% for rectal cancer, but the gap persists regardless of coverage status [9].

The screening rate for non-Hispanic white Americans stands at 74.4%, compared to 70.9% for Black/African Americans, 61.7% for Hispanic Americans, and 59.5% for Asian Americans [10]. These differences endure even within the same insurance cohort, suggesting that access alone does not explain the disparity. Patient-level barriers in underserved populations include lack of knowledge about screening, medical distrust, language barriers, and competing health demands [10].

Rural residents face additional structural obstacles: lower rates of private insurance coverage, fewer gastroenterologists per capita, and longer travel distances to colonoscopy facilities [9].

International Comparison: Is This a U.S. Problem?

Rising early-onset colorectal cancer incidence has been documented in Australia, Canada, New Zealand, the United Kingdom, and several other high-income countries [6][11]. A Lancet Oncology analysis found the highest age-standardized incidence rates among younger adults in Australia (16.5 per 100,000), Puerto Rico (15.2), the United States (14.8), New Zealand (14.8), and South Korea (14.3) [6].

All countries analyzed showed increasing incidence in successive birth cohorts since 1960, and an age-cohort model fit the data better than an age-period model across all four countries examined, although including nonlinear period effects also improved model fit [6].

Screening policy responses have varied. The U.S. lowered its recommended colorectal cancer screening age from 50 to 45 in 2021 [12]. Australia followed in July 2024, also moving its national bowel cancer screening program start age to 45 [11]. Canada, by contrast, generally recommends screening from age 50 for average-risk individuals, with the fecal immunochemical test (FIT) offered every two years rather than colonoscopy [11]. The UK's NHS bowel screening program begins at 56 (being extended down to 50) but does not yet recommend screening at 45.

Countries with organized, population-based FIT screening programs — where test kits are mailed directly to eligible residents — tend to have higher uptake than those relying on opportunistic screening driven by individual physician referral [11].

Source: WHO Global Health Observatory

Data as of Dec 31, 2022CSV

What Is Driving the Birth-Cohort Effect?

Researchers have proposed multiple biological and behavioral mechanisms, but none has been conclusively established as the primary driver.

Ultra-processed food and Western diet. Diets high in processed and ultra-processed foods are suspected of disrupting the gut microbiome in ways that promote colorectal carcinogenesis. Specific toxigenic bacterial species in low-diversity gut microbiomes produce N-nitroso compounds and hydrogen sulfide, which can cause DNA alkylation and genetic mutations in gastrointestinal cells [13][14]. The generation-over-generation increase in ultra-processed food consumption since the 1970s tracks temporally with the birth-cohort effect.

Gut microbiome disruption. Antibiotic exposure in childhood, cesarean delivery, formula feeding, and early-life diets may alter the developing microbiome in ways that create a "multi-hit" pathway toward cancer [13][15]. Colibactin — a genotoxin produced by certain E. coli strains — has been identified as one such "hit" [15]. Early-onset colorectal cancers show distinct microbial signatures compared to later-onset disease [14].

Obesity. The United States has the highest adult obesity prevalence among major developed nations at 42%, compared to 30.2% in Australia and 26.8% in the UK [WHO data]. Obesity drives dysregulation of endocrine, immune, and metabolic systems and promotes colon cancer cell proliferation [13]. However, many early-onset patients are not obese, and the correlation at the individual level is inconsistent.

Sedentary behavior. Physical inactivity is an established colorectal cancer risk factor, but its contribution to the generational shift has not been isolated from dietary and metabolic variables.

The honest assessment is that researchers suspect a convergence of exposures — a "multi-hit" model — rather than any single cause [13][15]. The scientific literature on the topic has expanded rapidly, with more than 15,900 papers on early-onset colorectal cancer published in 2024 alone, up from roughly 2,200 in 2011 [OpenAlex data].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Screening: The Gap Between Policy and Practice

The U.S. Preventive Services Task Force lowered the recommended colorectal cancer screening age from 50 to 45 in 2021 [12]. Uptake among the newly eligible 45-to-49 age group has improved but remains low. As of 2022, approximately two-thirds of adults aged 45 to 49 had never been screened for colorectal cancer [16]. Screening prevalence in this age group reached roughly 37% by recent estimates [3], up from about 20% in 2021, but still far below the rates seen among older adults [16][17].

Source: ACS / CDC BRFSS

Data as of Jan 1, 2025CSV

After the guideline change, local-stage colorectal cancer diagnoses in the 45-to-49 age group rose steeply — a 50% relative increase, from 11.7 to 17.5 cases per 100,000 between 2021 and 2022 — reflecting increased screening activity catching cancers earlier [17].

However, the age threshold itself has limits. Half of early-onset colorectal cancer cases occur before age 45, meaning even full compliance with the current recommendation would miss a substantial share of affected millennials [18]. One analysis estimated that lowering the screening age to 45 would prevent roughly one to two additional deaths per year — a modest absolute number [18].

The question of expanding screening further faces resistance. A Nature analysis published in 2026 noted that some countries' decisions to lower screening ages may cause more harm than good through overdiagnosis — detecting cancers that would never have become clinically significant — and the resource burden of screening larger populations [19].

The Steelman Case for Caution

Several epidemiologists have raised concerns that "rapid rise" framing can be statistically misleading when applied to low-incidence groups [18][19].

The absolute lifetime risk of colorectal cancer for a person in their 20s or 30s remains low — approximately 4%, or one in 25 [18]. Incidence among people in their 30s rose from 2.8 to 6.4 per 100,000 between 2006 and 2016 — a large relative increase, but still small in absolute terms [18]. At these base rates, percentage changes can appear volatile without representing a large shift in actual case counts.

Birth-cohort analysis itself carries methodological constraints. Age-period-cohort models must make assumptions to separate the effects of aging, calendar time, and birth year, and small variations in model specification can shift results. Researchers have cautioned that results should be interpreted carefully, particularly in countries where adjusted scores fall near statistical thresholds [6].

The characterization of the trend as an "epidemic" has been questioned. "The uptick is noticeable, but it's not a sea change either," wrote McGill University's Office for Science and Society [18]. Only one in ten moderately sized colon polyps progresses to invasive cancer, and 90% of colorectal cancer cases still occur after age 50 [18].

That said, the counterargument is straightforward: the rate of increase, sustained over more than two decades and confirmed across multiple countries, is real and accelerating. Rectal cancer's share of colorectal cancer diagnoses is growing. And the seven-month diagnostic delay facing young patients represents a systemic failure that inflates mortality regardless of base-rate debates.

Projections: What Happens by 2035?

Using ARIMA machine learning models applied to the 1999–2023 data, the SUNY Upstate team projected that rectal cancer deaths among adults 20 to 44 will continue rising through 2035, assuming current patterns hold [1][4]. Specifically, rectal cancer deaths among men in this age group are projected to reach 459 per year by 2035 — 90 more than in 2023 — and 304 among women, an increase of 60 [1].

If these projections hold, rectal cancer deaths could exceed colon cancer deaths in people under 50 by 2035, representing a reversal of the historical pattern [1][4].

Global modeling from GLOBOCAN projects that overall colorectal cancer incidence and mortality will rise substantially worldwide through 2050, driven heavily by increases in younger populations and in low- and middle-income countries [20].

The healthcare cost implications are significant but difficult to isolate. Colorectal cancer treatment — particularly for late-stage rectal cancer requiring surgery, radiation, and chemotherapy — is among the most expensive cancer care pathways. The combination of more cases, later-stage diagnoses, and patients in their prime working years amplifies both direct treatment costs and lost economic productivity. However, precise cost projections specific to the millennial cohort have not been published.

What Can Be Done

Dr. Ben Schlechter of Dana-Farber Cancer Institute framed the clinical imperative bluntly: "This is a medical crisis. This is not something that should be ignored" [1].

Several actionable steps are supported by the evidence. Expanding screening access and uptake among 45-to-49-year-olds remains the nearest-term intervention. Reducing diagnostic delays — particularly by training primary care physicians to take rectal bleeding in young patients seriously rather than defaulting to a hemorrhoids diagnosis — could shift stage at diagnosis earlier. Addressing racial and socioeconomic disparities in treatment quality is a separate but related priority.

The research community, meanwhile, is racing to identify which combination of early-life exposures drives the birth-cohort effect. Until that question is answered, prevention strategies remain broad rather than targeted: maintain a healthy weight, limit ultra-processed food intake, stay physically active, and be aware of symptoms including rectal bleeding, changes in bowel habits, and unexplained weight loss.

The data are clear that something changed for people born after 1960, and each subsequent generation has faced higher risk. The debate is over magnitude, mechanism, and how aggressively to intervene — not over whether the trend exists.